Application of Indocyanine Green Labeled Fluorescent Laparoscopy in Proximal Gastric Cancer
Primary Purpose
Gastric Cancer
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
indocyanine green labeled fluorescent laparoscopy
Sponsored by
About this trial
This is an interventional treatment trial for Gastric Cancer focused on measuring Indocyanine green
Eligibility Criteria
Inclusion Criteria:
- 18 years old < age < 75 years old
- The primary gastric lesion was pathologically diagnosed as proximal gastric adenocarcinoma by endoscopic biopsy (papillary adenocarcinoma PAP, tubular adenocarcinoma TUB, mucinous adenocarcinoma MUC, signed-ring cell carcinoma SIG, poorly differentiated adenocarcinoma POR)
- Preoperative clinical staging was CT1-4A, N-/+, and M0, according to AJCC-8th TNM tumor staging
- No distant metastasis was found in preoperative examination, and the tumor did not directly invade pancreas, spleen or other adjacent organs
- ECOG physical status score 0/1 before surgery Preoperative ASA score I-III
(7) Informed consent of patients
Exclusion Criteria:
- Suffering from severe mental illness
- Severe complications cannot tolerate surgery
- Simultaneous surgical treatment of other diseases is required
- History of gastric surgery (including ESD/EMR for gastric cancer)
- Tumors involving esophagus or duodenum were confirmed preoperatively
- Neoadjuvant therapy has been implemented
- Leather stomach
- Refusing laparoscopic surgery
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
indocyanine green labeled fluorescent laparoscopy
The pathological staging
Arm Description
The experimental group was marked with indocyanine green, while the control group was not marked with indocyanine green
They were grouped by different pathological stages
Outcomes
Primary Outcome Measures
Three-year disease-free survival rate
To evaluate the difference of 3-year disease-free survival rate between the experimental group and the control group
Secondary Outcome Measures
lymph node positive rate
To evaluate the difference oflymph node positive rate between the experimental group and the control group
Incidence of early complications
The incidence of lymphatic leakage, shock and gastric stump leakage were used as secondary outcome measures
operative mortality
To investigate whether the mortality of laparoscopic proximal gastric cancer surgery marked with indocyanine green was lower than that of the control group
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05369117
Brief Title
Application of Indocyanine Green Labeled Fluorescent Laparoscopy in Proximal Gastric Cancer
Official Title
To Evaluate Whether the Clinical Efficacy of Laparoscopic Lymph Node Dissection With Indocyanine Green Tracer is Better Than Without Indocyanine Green Tracer
Study Type
Interventional
2. Study Status
Record Verification Date
May 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
May 31, 2022 (Anticipated)
Primary Completion Date
May 1, 2027 (Anticipated)
Study Completion Date
May 6, 2027 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Guangyong Zhang
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Recently, laparoscopic gastrectomy has been gradually accepted by surgeons worldwide for gastric cancer treatment. Complete dissection of the lymph nodes and the establishment of the surgical margin are the most important considerations for curative gastric cancer surgery. Previous studies have demonstrated that indocyanine green (ICG)-traced laparoscopic gastrectomy significantly improves the completeness of lymph node dissection. However, it remains difficult to identify the tumor location intraoperatively for gastric cancers that are staged ≤T3. Here, the investigatorsinvestigated the feasibility of ICG fluorescence for lymph node mapping and tumor localization during totally laparoscopic distal gastrectomy.Preoperative and perioperative data from consecutive patients with gastric cancer who underwent a laparoscopic proximal gastrectomy were collected and analyzed. The investigators want to know if near-infrared fluorescence imaging with ICG can be successfully used in laparoscopic proximal gastrectomy, and if it contributes to both the completeness of D2 lymph node dissection and confirmation of the gastric transection line. The application of ICG labeled near infrared imaging fluorescence laparoscopic technology is still in the stage of exploration and experience accumulation, and it needs to be comprehensively evaluated through a large number of prospective randomized controlled studies.
Detailed Description
Recently, laparoscopic gastrectomy has been gradually accepted by surgeons worldwide for gastric cancer treatment. Complete dissection of the lymph nodes and the establishment of the surgical margin are the most important considerations for curative gastric cancer surgery. Previous studies have demonstrated that indocyanine green (ICG)-traced laparoscopic gastrectomy significantly improves the completeness of lymph node dissection. However, it remains difficult to identify the tumor location intraoperatively for gastric cancers that are staged ≤T3. Here, the investigatorsinvestigated the feasibility of ICG fluorescence for lymph node mapping and tumor localization during totally laparoscopic distal gastrectomy.Preoperative and perioperative data from consecutive patients with gastric cancer who underwent a laparoscopic proximal gastrectomy were collected and analyzed. The investigators want to know if near-infrared fluorescence imaging with ICG can be successfully used in laparoscopic proximal gastrectomy, and if it contributes to both the completeness of D2 lymph node dissection and confirmation of the gastric transection line. The application of ICG labeled near infrared imaging fluorescence laparoscopic technology is still in the stage of exploration and experience accumulation, and it needs to be comprehensively evaluated through a large number of prospective randomized controlled studies.By recruiting patients and signing informed consent, randomized control was used to divide patients into the experimental group (fluorescently labeled fluorescently laparoscopic proximal gastric cancer surgery) and the control group (fluorescently labeled fluorescently laparoscopic proximal gastric cancer surgery). In the experimental group, indocyanine green fluorescence labeling was performed under gastroscope before surgery and internal jugular vein puncture was performed routinely for better fluid replenishment after surgery. Lymph nodes and diseased stomach tissues were collected during operation. Postoperative assessment was made for ICU support, routine acid-suppressing therapy, prophylactic antibiotics, analgesia, and nausea suppression. The patients were followed up for 3 years. The primary outcome was 3-year disease-free survival, and the secondary outcome was lymph node positive rate, early complication rate and surgical mortality. The investigators plan to obtain more precise evidence-based medical evidence through this project.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastric Cancer
Keywords
Indocyanine green
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
1016 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
indocyanine green labeled fluorescent laparoscopy
Arm Type
Experimental
Arm Description
The experimental group was marked with indocyanine green, while the control group was not marked with indocyanine green
Arm Title
The pathological staging
Arm Type
Experimental
Arm Description
They were grouped by different pathological stages
Intervention Type
Behavioral
Intervention Name(s)
indocyanine green labeled fluorescent laparoscopy
Intervention Description
indocyanine green fluorescence labeling was performed under gastroscope before surgery and internal jugular vein puncture was performed routinely for better fluid replenishment after surgery
Primary Outcome Measure Information:
Title
Three-year disease-free survival rate
Description
To evaluate the difference of 3-year disease-free survival rate between the experimental group and the control group
Time Frame
Through study completion,an average of 3 years
Secondary Outcome Measure Information:
Title
lymph node positive rate
Description
To evaluate the difference oflymph node positive rate between the experimental group and the control group
Time Frame
up to 1 week
Title
Incidence of early complications
Description
The incidence of lymphatic leakage, shock and gastric stump leakage were used as secondary outcome measures
Time Frame
up to 1 week
Title
operative mortality
Description
To investigate whether the mortality of laparoscopic proximal gastric cancer surgery marked with indocyanine green was lower than that of the control group
Time Frame
up to 24 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
18 years old < age < 75 years old
The primary gastric lesion was pathologically diagnosed as proximal gastric adenocarcinoma by endoscopic biopsy (papillary adenocarcinoma PAP, tubular adenocarcinoma TUB, mucinous adenocarcinoma MUC, signed-ring cell carcinoma SIG, poorly differentiated adenocarcinoma POR)
Preoperative clinical staging was CT1-4A, N-/+, and M0, according to AJCC-8th TNM tumor staging
No distant metastasis was found in preoperative examination, and the tumor did not directly invade pancreas, spleen or other adjacent organs
ECOG physical status score 0/1 before surgery Preoperative ASA score I-III
(7) Informed consent of patients
Exclusion Criteria:
Suffering from severe mental illness
Severe complications cannot tolerate surgery
Simultaneous surgical treatment of other diseases is required
History of gastric surgery (including ESD/EMR for gastric cancer)
Tumors involving esophagus or duodenum were confirmed preoperatively
Neoadjuvant therapy has been implemented
Leather stomach
Refusing laparoscopic surgery
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Application of Indocyanine Green Labeled Fluorescent Laparoscopy in Proximal Gastric Cancer
We'll reach out to this number within 24 hrs